The primary aim of the present protocol is to determine the role of chenodeoxycholate for postprandial GLP-1 responses (and the resulting metabolic consequences) in humans.
ID
Source
Brief title
Condition
- Metabolic and nutritional disorders congenital
- Glucose metabolism disorders (incl diabetes mellitus)
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Plasma bile acids, GLP-1, glucose
Secondary outcome
free fatty acidsn,thyroid hormones, resting energy expenditure
Background summary
Bile acids (BAs) have traditionally been regarded as nutrient-emulgators but
may play an important role in energy metabolism. Primary bile acids are
secreted in the bile and are dehydroxylated by the bacterial flora in the colon
to form the secondary bile acids. BAs may stimulate the production of
glucagon-like peptide-1 (GLP-1) that stimulates insulin secretion and inhibits
glucagon secretion in the pancreas in a glucose-dependent fashion.
Additionally, it reduces gastrointestinal motility and appetite.
Cerebrotendinous xanthomatosis (CTX, OMIM #213700) is an autosomal recessive
disorder characterized by a deficiency of sterol 27-hydroxylase leading to a
defective BA synthesis (decreased amount of the BA chenodeoxycholate (CDCA)).
It is not known whether CTX patients exhibit physiological deficiencies with
regard to postprandial plasma GLP-1 responses, glucose uptake, free fatty acid
(FFA) suppression and plasma insulin levels. Studying postprandial glucose
metabolism in these patients will provide insight in the metabolic role of BAs.
We hypothesize that CTX patients, when untreated, have lower postprandial GLP-1
and insulin levels with higher plasma glucose and FFA levels compared to
matched healthy control subjects.
Study objective
The primary aim of the present protocol is to determine the role of
chenodeoxycholate for postprandial GLP-1 responses (and the resulting metabolic
consequences) in humans.
Study design
Compare the metabolic response to a mixed meal test between 14 CTX patients and
14 healthy matched controls.
Study burden and risks
Peripheral (underarm) i.v. cannula, 5 hours stay in AMC
Meibergdreef 9
1105 AZ
NL
Meibergdreef 9
1105 AZ
NL
Listed location countries
Age
Inclusion criteria
*Adult age (older than 18 years of age)
*Body mass index 19*30 kg/m2
*General good health (normal liver and renal function)
*HbA1c below 7%
*Ability to give informed consent
Exclusion criteria
Since CTX is a rare disorder, little exclusion criteria exist. However, patients that use
medication that interferes with glucose metabolism such as oral antidiabetic medication or
insulin are not included.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL35575.018.11 |